DFS and OS are significantly higher in the CHOP+Rituximab group (p<0.03 and p<0.04, respectively). Our study had no HBV, HCV reactivation. Conclusion: The addition of rituximab to the CHOP regimen increases the complete response rate and prolongs DFS and OS in patients with DLCL CD20 (+), without a significant increase in toxicity.